Indications and uses
ANTI DANDRUFF
ANTI DANDRUFF
ANTI DANDRUFF
SELENIUM SULFIDE 1%
SEBORRHEIC DERMATITIS IN AREAS OTHER THAN THE SCALP
FOR RELIEF OF FLAKING AND ITCHING DUE TO DANDRUFF, AND SEBORRHEIC DERMATITIS, AND TO HELP PREVENT THE CHANCE OF RE-OCCURRENCE.
FRONT AND BACK LABELS: cvs11.jpg
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 86fffa7b-d382-4771-a253-25cccb64b590 | Product name | 3 | 20251124 |
| 0306390c-dd77-4363-afe0-63c58088b2a1 | Product name | 1 | 20220120 |
| 503ea967-4b9c-48cf-9e87-c7975295849d | Product name | 2 | 20220120 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 59779-610-11 | 2020-01-31 | C162847 | 48780-1 | 9d75b9cf-f86f-f424-e053-dadaa90a57ce | Drug Facts Box - Back Label |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 59779-610-11 | ANTIDANDRUFF MEDICATED | 325 mL in 1 BOTTLE, PLASTIC | SHAMPOO | 325 | 1 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SELENIUM SULFIDE | ACTIVE INGREDIENT | Z69D9E381Q | 1 | |
| SELENIUM | ACTIVE MOIETY | H6241UJ22B | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 59779-610 | 59779-610-11 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SELENIUM SULFIDE | Z69D9E381Q | ACTIB |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 710a6dff-4a6b-4ff5-8bae-790c49102776 | a0838913-ae3e-4274-8e2a-d37ae177a915 | 2010-07-06 | Warnings | 710a6dff-4a6b-4ff5-8bae-790c49102776 a0838913-ae3e-4274-8e2a-d37ae177a915 |
Adverse event summaries are temporarily unavailable. Other product information remains available.